Page 11 - Refractory Multiple News Today

119 Abstracts and Presentations Featuring Sarah Cannon's Clinical Research and Care Insights Today, Sarah Cannon announced it will present its latest cancer research insights at the American Society

Eighteen-month follow-up data from pivotal CARTITUDE-1 study, including progression-free-survival data, to be presented at ASCO and EHA Annual Meetings Findings from the Phase 2 CARTITUDE-2 study

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 30 company-sponsored studies, including six oral...

Further analysis from the Phase 3 ANDROMEDA study presented at the 2021 ASCO Annual Meeting also show doubling rates of organ response with no new safety signals The Janssen Pharmaceutical Companies

(1) Application based on positive Phase 1b/2 data from the CARTITUDE-1 study and follows confirmation of accelerated assessment by the Committee for Medicinal Products for Human Use of the European Medicines Agency The Janssen Pharmaceutical Companies of Johnson Johnson announced today that they have submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) seeking approval of cilta-cel, an investigational B cell maturation antigen (BCMA)-directed chimeric ant...

Bristol Myers Squibb to build new cell therapy manufacturing site in the Netherlands Bristol Myers Squibb (BMS) will build a new cell therapy manufacturing site in Leiden, the Netherlands: marking the company’s first cell therapy manufacturing facility in Europe and its fifth globally. BMS is building up its cell manufacturing footprint and network across the globe. The American pharmaceutical company currently has cell therapy manufacturing facilities in the US: ...